In the CLEAR Outcomes trial, bempedoic acid lowered plasma LDL-cholesterol levels and reduced the incidence of major adverse cardiovascular events in individuals who were intolerant to statin therapy.doi:10.1038/s41569-023-00863-5Lim, Gregory B....
Bempedoic acidis a novel drug that inhibits the same cholesterol biosynthesis pathway asstatins; specifically, this drug takes effect two steps upstream from the rate-limiting HMG-CoA reductase reaction. Like statins, bempedoic suppresses cholesterol synthesis, which triggers increasedLDL receptorson the...
ATP-citrate lyase (ACL) is an enzyme found two levels above HMG-CoA reductase in the cholesterol synthesis pathway. Due to similarity in the mechanism of action, bempedoic acid, like statins, decreases hepatic generation of cholesterol, upregulates the LDL receptor expression on liver, and ...
The 12-week study met its primary endpoints as well as key secondary endpoints, including that the bempedoic acid / ezetimibe FDC tablet: Significantly lowered Low-Density Lipoprotein Cholesterol (LDL-C) by 40% compared to placebo Reduced high-sensitivity C-Reactive Protein (hsCRP), an important...
Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers low-density lipoprotein cholesterol (LDL-C) by inhibition of cholesterol synthesis in the liver. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynth...
Conclusion The bempedoic acid and ezetimibe fixed-dose combination significantly lowered low-density lipoprotein cholesterol versus placebo or other oral monotherapies and had a favourable safety profile when added to maximally tolerated statin therapy in patients with hypercholesterolemia and high ...
Cholesterol-lowering drugsMetabolic syndrome (MetS) is associated with increased risk of cardiovascular events. Bempedoic acid (BA) is an ATP citrate lyase inhibitor that lowers LDL-C in patients with hypercholesterolemia. We investigated the lipid-lowering efficacy, safety, and effect of BA on ...
Conclusions: In patients with hypercholesterolemia unable to take statins, bempedoic acid lowered LDL-C levels by a mean of 26.5% vs placebo and bempedoic acid + ezetimibe fixed-dose combination lowered LDL-C by 39.2%. The treatments were generally well tolerated, suggesting that bempedoic acid ...
Bempedoic acid added to background PCSK9i therapy significantly lowered LDL-C by 30.3% (P < .001) vs placebo. Compared with placebo, bempedoic acid significantly lowered apolipoprotein B, non鈥揾igh-density lipoprotein cholesterol, and total cholesterol (nominal P < .001 for all), and high-...